Fig. 4: Targeting mTORC2 inhibits glycolysis and lactate secretion. | Cancer Gene Therapy

Fig. 4: Targeting mTORC2 inhibits glycolysis and lactate secretion.

From: Targeting mTORC2 in lung squamous cell carcinoma improves anti-tumor immunity through the PSGL-1-VISTA axis

Fig. 4

Seahorse analysis of (A) extracellular acidification rate (ECAR), (B) glycolysis, glycolytic capacity, and glycolytic reserve and (C) in vitro lactate concentrations in HCC2814 WT vs MLST8-KO. Seahorse analysis of (D) extracellular acidification rate (ECAR), (E) glycolysis, glycolytic capacity, and glycolytic reserve and (F) in vitro lactate concentrations in H596 WT vs MLST8-KO. Seahorse analysis of (G) extracellular acidification rate (ECAR), (H) glycolysis, glycolytic capacity, and glycolytic reserve and (I) in vivo tumor interstitial lactate concentrations in KLN205-Ptennull WT vs Mlst8-KO. All data are presented as mean ± SEM from two or three independent experiments. p values were determined by two-tailed unpaired Student t test. *p < 0.05, **p < 0.01.

Back to article page